These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

409 related items for PubMed ID: 16940406

  • 1. Low-dose orlistat effects on body weight of mildly to moderately overweight individuals: a 16 week, double-blind, placebo-controlled trial.
    Anderson JW, Schwartz SM, Hauptman J, Boldrin M, Rossi M, Bansal V, Hale CA.
    Ann Pharmacother; 2006 Oct; 40(10):1717-23. PubMed ID: 16940406
    [Abstract] [Full Text] [Related]

  • 2. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance.
    Toplak H, Ziegler O, Keller U, Hamann A, Godin C, Wittert G, Zanella MT, Zúñiga-Guajardo S, Van Gaal L.
    Diabetes Obes Metab; 2005 Nov; 7(6):699-708. PubMed ID: 16219013
    [Abstract] [Full Text] [Related]

  • 3. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study.
    Muls E, Kolanowski J, Scheen A, Van Gaal L, ObelHyx Study Group.
    Int J Obes Relat Metab Disord; 2001 Nov; 25(11):1713-21. PubMed ID: 11753595
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of 12 weeks supplementation of a botanical extract-based weight loss formula on body weight, body composition and blood chemistry in healthy, overweight subjects--a randomised double-blind placebo-controlled clinical trial.
    Opala T, Rzymski P, Pischel I, Wilczak M, Wozniak J.
    Eur J Med Res; 2006 Aug 30; 11(8):343-50. PubMed ID: 17052970
    [Abstract] [Full Text] [Related]

  • 5. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group.
    Rössner S, Sjöström L, Noack R, Meinders AE, Noseda G.
    Obes Res; 2000 Jan 30; 8(1):49-61. PubMed ID: 10678259
    [Abstract] [Full Text] [Related]

  • 6. Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study.
    Richelsen B, Tonstad S, Rössner S, Toubro S, Niskanen L, Madsbad S, Mustajoki P, Rissanen A.
    Diabetes Care; 2007 Jan 30; 30(1):27-32. PubMed ID: 17192328
    [Abstract] [Full Text] [Related]

  • 7. Effects of orlistat on obesity-related diseases - a six-month randomized trial.
    Guy-Grand B, Drouin P, Eschwège E, Gin H, Joubert JM, Valensi P.
    Diabetes Obes Metab; 2004 Sep 30; 6(5):375-83. PubMed ID: 15287931
    [Abstract] [Full Text] [Related]

  • 8. Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients.
    Kopelman P, Bryson A, Hickling R, Rissanen A, Rossner S, Toubro S, Valensi P.
    Int J Obes (Lond); 2007 Mar 30; 31(3):494-9. PubMed ID: 16953261
    [Abstract] [Full Text] [Related]

  • 9. Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial.
    Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA.
    Hepatology; 2009 Jan 30; 49(1):80-6. PubMed ID: 19053049
    [Abstract] [Full Text] [Related]

  • 10. Effect of orlistat on cardiovascular disease risk in obese adults.
    Swinburn BA, Carey D, Hills AP, Hooper M, Marks S, Proietto J, Strauss BJ, Sullivan D, Welborn TA, Caterson ID.
    Diabetes Obes Metab; 2005 May 30; 7(3):254-62. PubMed ID: 15811142
    [Abstract] [Full Text] [Related]

  • 11. Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia.
    Dujovne CA, Zavoral JH, Rowe E, Mendel CM, Silbutramine Study Group.
    Am Heart J; 2001 Sep 30; 142(3):489-97. PubMed ID: 11526363
    [Abstract] [Full Text] [Related]

  • 12. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
    Derosa G, Cicero AF, Murdolo G, Ciccarelli L, Fogari R.
    Diabetes Nutr Metab; 2004 Aug 30; 17(4):222-9. PubMed ID: 15575343
    [Abstract] [Full Text] [Related]

  • 13. Use of sibutramine in obese mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial.
    García-Morales LM, Berber A, Macias-Lara CC, Lucio-Ortiz C, Del-Rio-Navarro BE, Dorantes-Alvárez LM.
    Clin Ther; 2006 May 30; 28(5):770-82. PubMed ID: 16861099
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients.
    Derosa G, Cicero AF, Murdolo G, Piccinni MN, Fogari E, Bertone G, Ciccarelli L, Fogari R.
    Diabetes Obes Metab; 2005 Jan 30; 7(1):47-55. PubMed ID: 15642075
    [Abstract] [Full Text] [Related]

  • 15. A randomized double-blind study comparing the efficacy and safety of orlistat versus placebo in obese patients with mild to moderate hypercholesterolemia.
    de Castro JJ, Dias T, Chambel P, Carvalheiro M, Correia LG, Guerreiro L, Marques O, Medina JL, Nobre E, Nunes JS, Pereiraa MC, Polónia J, Portugal J, Raimundo A, Ruas A, da Silva PM, Vasconcelos C, Reis JL, Teles AG.
    Rev Port Cardiol; 2009 Dec 30; 28(12):1361-74. PubMed ID: 20301983
    [Abstract] [Full Text] [Related]

  • 16. Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial.
    Wadden TA, Berkowitz RI, Womble LG, Sarwer DB, Arnold ME, Steinberg CM.
    Obes Res; 2000 Sep 30; 8(6):431-7. PubMed ID: 11011909
    [Abstract] [Full Text] [Related]

  • 17. Long-term weight loss decreases the nontraditional cardiovascular risk factors interleukin-18 and matrix metalloproteinase-9 in obese subjects.
    Madsen EL, Bruun JM, Skogstrand K, Hougaard DM, Christiansen T, Richelsen B.
    Metabolism; 2009 Jul 30; 58(7):946-53. PubMed ID: 19409578
    [Abstract] [Full Text] [Related]

  • 18. Comparison of the effects of sibutramine and orlistat on obese, poorly-controlled type 2 diabetic patients.
    Chou KM, Huang BY, Fanchiang JK, Chen CH.
    Chang Gung Med J; 2007 Jul 30; 30(6):538-46. PubMed ID: 18350737
    [Abstract] [Full Text] [Related]

  • 19. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease.
    Zelber-Sagi S, Kessler A, Brazowsky E, Webb M, Lurie Y, Santo M, Leshno M, Blendis L, Halpern Z, Oren R.
    Clin Gastroenterol Hepatol; 2006 May 30; 4(5):639-44. PubMed ID: 16630771
    [Abstract] [Full Text] [Related]

  • 20. Use of polyglucosamine and physical activity to reduce body weight and dyslipidemia in moderately overweight subjects.
    Cornelli U, Belcaro G, Cesarone MR, Cornelli M.
    Minerva Cardioangiol; 2008 Oct 30; 56(5 Suppl):71-8. PubMed ID: 19597412
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.